Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma

Hepatology Research

Volumn 45, Issue 2, 2015, Pages 190-200

  Xie, Zhi Bo ^a   Wang, Xiao Bo ^a   Peng, Yu Chong ^a   Zhu, Shao Liang ^a   Ma, Liang ^a   Xiang, Bang De ^a   Gong, Wen Feng ^a   Chen, Jie ^a   You, Xue Mei ^a   Jiang, Jing Hang ^a   Li, Le Qun ^a   Zhong, Jian Hong ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Drug eluting beads; Hepatocellular carcinoma; Inoperable; Meta analysis; Transarterial chemoembolization

Indexed keywords

ANTINEOPLASTIC AGENT;

CHEMOEMBOLIZATION; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG ELUTING BEAD; DRUG ELUTING BEAD TRANSARTERIAL CHEMOEMBOLIZATION; DRUG SAFETY; EMBOLIC PARTICLE; HAZARD RATIO; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; META ANALYSIS; OVERALL SURVIVAL; PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK RATIO; SYSTEMATIC REVIEW; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84921522198     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12450     Document Type: Review

References (56)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127 (12): 2893-2917.
2. Lo CM, Ngan H, Tso WK etal. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35 (5): 1164-1171.
3. Llovet JM, Real MI, Montana X etal. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 (9319): 1734-1739.
4. Lammer J, Malagari K, Vogl T etal. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (1): 41-52.
5. Varela M, Real MI, Burrel M etal. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46 (3): 474-481.
6. Poon RT, Tso WK, Pang RW etal. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007; 5 (9): 1100-1108.
7. Kettenbach J, Stadler A, Katzler IV etal. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 2008; 31 (3): 468-476.
8. Malagari K, Alexopoulou E, Chatzimichail K etal. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 2008; 33 (5): 512-519.
9. Lewis AL, Gonzalez MV, Lloyd AW etal. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006; 17 (2 Pt 1): 335-342.
10. Malagari K, Pomoni M, Kelekis A etal. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33 (3): 541-551.
11. Vogl TJ, Lammer J, Lencioni R etal. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 2011; 197 (4): W562-570.
12. Grosso M, Vignali C, Quaretti P etal. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 2008; 31 (6): 1141-1149.
13. Malagari K, Chatzimichael K, Alexopoulou E etal. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008; 31 (2): 269-280.
14. Song MJ, Chun HJ, Song do S etal. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57 (6): 1244-1250.
15. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101 (6): 476-480.
16. Sacco R, Bargellini I, Bertini M etal. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22 (11): 1545-1552.
17. Recchia F, Passalacqua G, Filauri P etal. Chemoembolization of unresectable hepatocellular carcinoma: decreased toxicity with slow-release doxorubicineluting beads compared with lipiodol. Oncol Rep 2012; 27 (5): 1377-1383.
18. Golfieri R, Giampalma E, Renzulli M etal. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111: 255-264.
19. Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res 2010; 40 (10): 943-953.
20. Therasse P, Arbuck SG, Eisenhauer EA etal. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92 (3): 205-216.
21. Eisenhauer E, Therasse P, Bogaerts J etal. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (2): 228-247.
22. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35 (3): 421-430.
23. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.0. 2. Updated September 2009. The Cochrane Collaboration. 2009. Accessed October 6, 2010.
24. Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ 1998; 316 (7129): 469; author reply 470-1.
25. Sterne JA, Sutton AJ, Ioannidis JP etal. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002.
26. Lencioni R, Malagari K, Vogl T etal. A randomized phase II trial of a drug eluting bead in the treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization. J Clin Oncol 2009; 27: 41-52.
27. van Malenstein H, Maleux G, Vandecaveye V etal. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34 (7): 368-376.
28. Ferrer Puchol MD, la Parra C, Esteban E etal. Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma. Radiologia 2011; 53 (3): 246-253.
29. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35 (3): 519-524.
30. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (4): 908-943.
31. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014; 63 (5): 844-855.
32. Gao S, Yang Z, Zheng Z etal. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60 (124): 813-820.
33. Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29 (5): 920-925.
34. Wiggermann P, Sieron D, Brosche C etal. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit 2011; 17 (4): CR189-195.
35. Boily G, Villeneuve JP, Lacoursiere L etal. Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. HPB 2014; [Epub ahead of print].
36. Tsochatzis EA, Fatourou E, O'Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20 (12): 3069-3077.
37. Meyer T, Kirkwood A, Roughton M etal. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 2013; 108 (6): 1252-1259.
38. Marelli L, Stigliano R, Triantos C etal. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30 (1): 6-25.
39. Xie ZB, Ma L, Wang XB etal. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. Tumour Biol 2014; 35: 8451-8459.
40. Karaman B, Battal B, Oren NC, Ustunsoz B, Yagci G. Acute ischemic cholecystitis after transarterial chemoembolization with drug-eluting beads. Clin Imaging 2012; 36 (6): 861-864.
41. Khan I, Vasudevan V, Nallagatla S, Arjomand F, Ali R. Acute lung injury following transcatheter hepatic arterial chemoembolization of doxorubicin-loaded LC beads in a patient with hepatocellular carcinoma. Lung India 2012; 29 (2): 169-172.
42. Lesevic V, Marzano E, Greget M, Rosso E, Bachellier P, Pessaux P. Severe complication after a doxorubicin-eluting-bead embolization: surgical management and pathological findings. Cardiovasc Intervent Radiol 2011; 34 (Suppl 2): S186-189.
43. Ritter CO, Wartenberg M, Mottok A etal. Spontaneous liver rupture after treatment with drug-eluting beads. Cardiovasc Intervent Radiol 2012; 35 (1): 198-202.
44. Lee YJ, Kim GH, Park do Y etal. A case of epidural abscess occurred after liver abscess complicated by transarterial chemoembolization in a patient with metastatic cancer to liver. Korean J Gastroenterol 2013; 61 (4): 225-229.
45. Yakoshi Y, Toyoki Y, Ishido K etal. [A case of surgical resection of a combined hepatocellular and cholangiocarcinoma after transarterial chemoembolization]. Gan to Kagaku Ryoho 2013; 40 (12): 1798-1800.
46. Taupin D, Mukherjee V, Nathavitharana R, Green DA, Fridman D. Lipiodol embolism following transarterial chemoembolization: an atypical case. Crit Care Med 2014; 42 (6): e481-484.
47. Park HC, Park HB, Chung CY etal. Acute obstructive cholangitis complicated by tumor migration after transarterial chemoembolization: a case report and literature review. Korean J Gastroenterol 2014; 63 (3): 171-175.
48. Prajapati HJ, Dhanasekaran R, El-Rayes BF etal. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol 2013; 24 (3): 307-315.
49. Namur J, Citron SJ, Sellers MT etal. Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J Hepatol 2011; 55 (6): 1332-1338.
50. Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 2006; 17 (8): 1335-1343.
51. Padia SA, Shivaram G, Bastawrous S etal. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles. J Vasc Interv Radiol 2013; 24 (3): 301-306.
52. Sangro B. Chemoembolization and radioembolization. Best Pract Res Clin Gastroenterol 2014; 28 (5): 909-919.
53. Irie T, Kuramochi M, Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol 2013; 36 (3): 706-713.
54. Hecq JD, Lewis AL, Vanbeckbergen D etal. Doxorubicin-loaded drug-eluting beads (DC Bead(R)) for use in transarterial chemoembolization: a stability assessment. J Oncol Pharm Pract 2013; 19 (1): 65-74.
55. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006; 12 (8): 2563-2567.
56. Lencioni R, de Baere T, Burrel M etal. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 2012; 35 (5): 980-985.